The HIV shot that could change medicine is facing its biggest test: Getting to patients

Trials of lenacapavir, a drug developed by Gilead Sciences, show the twice-a-year shot is almost 100% effective at preventing HIV infection. Ihsaan Haffejee / AFP via Getty Images Gilead's lenacapavir shows near 100% efficacy in preventing HIV with twice-yearly shots, reports The Telegraph. Some Latin American countries face barriers to accessing lenacapavir despite running crucial trials. Beyond price, supply is constrained as Gilead works to scale up production of the sought-after shot. F...